Millie
your market intelligence analyst
Search Results
14 results
Your search is now limited to «Takeda» expert search.
Business Wire 05/25/2020 10:00
CAMBRIDGE, Massachusetts y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Bolsa de Valores de Tokio:4502/Bolsa de Valores de Nueva York:TAK) anunció hoy que la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobó ALUNBRIG (brigatinib) para pacientes adultos con cáncer de pulmón no microcítico metastásico (NSCLC) positivo para cinasa de linfoma anaplásico (ALK+) detectado mediante una evaluación aprobada por la FDA. Esta aprobación amplía la indicación actual.
Business Wire 05/24/2020 15:49
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) heeft vandaag aangekondigd dat de Amerikaanse Food en Drug Administration (FDA) ALUNBRIG (brigatinib) heeft goedgekeurd voor volwassen patiënten met anaplastic lymphoma kinase-positive (ALK +) metastatic non-small cell lung cancer (NSCLC) zoals gedetecteerd door de FDA goedgekeurde test.
Business Wire 05/24/2020 12:21
CAMBRIDGE, Massachusetts, und OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (Food and Drug Administration, FDA) die Zulassung für ALUNBRIG (Brigatinib) erteilt hat, und zwar für erwachsenen Patienten mit Anaplastische-Lymphom-Kinase (ALK)-positivem, metastasiertem nicht-kleinzelligem Lungenkrebs (NSCLC), der durch einen von der FDA anerkannten Test festgestellt wurde.
Business Wire 05/23/2020 19:59
CAMBRIDGE, Massachusetts e OSAKA, Japão--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunciou hoje que o FDA (Food and Drug Administration) dos EUA aprovou o ALUNBRIG (brigatinibe) para pacientes adultos com câncer de pulmão metástico de não-pequenas células (CPNPC) positivo para quinase de linfoma anaplásico (ALK+), conforme detectado por um teste aprovado pelo FDA.
Business Wire 05/22/2020 23:49
CAMBRIDGE, Massachusetts, et OSAKA, Japon--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE : 4502/NYSE : TAK) annonce ce jour que l’Agence américaine des produits alimentaires et médicamenteux (FDA) a approuvé ALUNBRIG (brigatinib) pour les patients adultes atteints d’un cancer du poumon non à petites cellules (CPNPC) à kinase positive du lymphome anaplasique (ALK+) métastatique, détecté par un test approuvé par la FDA.
Business Wire 05/22/2020 20:30
CAMBRIDGE, Massachusetts e OSAKA, Giappone--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) oggi ha annunciato che la FDA (Food and Drug Administration, l’agenzia federale statunitense per gli alimenti e i farmaci) ha approvato ALUNBRIG (brigatinib) per la terapia di pazienti con carcinoma polmonare non a piccole cellule (NSCLC) metastatico positivo per ALK (ALK+) quando rilevato tramite un’analisi approvata dalla FDA.
FP Trading Desk (Canada) 05/22/2020 16:30
− Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases CAMBRIDGE, Mass. & OSAKA, Japan — Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) [...]
Business Wire 05/22/2020 10:13
CAMBRIDGE (Massachusetts) y OSAKA (Japón)--(BUSINESS WIRE)--En el día de hoy, Takeda Pharmaceutical Company Limited (Bolsa de Valores de Tokio:4502/Bolsa de Valores de Nueva York:TAK) (en adelante, "Takeda") anunció que la compañía presentará datos de su cartera de productos oncológicos en expansión y de su cartera de productos consolidada en dos próximos congresos científicos virtuales: la 56.ª Reunión Anual de la Sociedad Americana de Oncología Clínica (ASCO), que se llevará a cabo del 29 al.

Food and Human Nutrition

Business Issues

Companies - Public

Companies - Venture Funded

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Products - Animal

Products - Plant

Political Entities

Strategic Scenarios

Sources

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications